Sylke Maas - BioNTech VP Strategy
| 22UA Stock | EUR 111.40 1.00 0.89% |
Insider
Sylke Maas is VP Strategy of BioNTech SE
| Phone | 49 6131 9084 0 |
| Web | https://www.biontech.de |
BioNTech Management Efficiency
The company has return on total asset (ROA) of 0.4283 % which means that it generated a profit of $0.4283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7624 %, meaning that it generated $0.7624 on every $100 dollars invested by stockholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Oscar Hamreus | Powercell Sweden | 42 | |
| HongBin Luo | BYD Company Limited | 57 | |
| Magnus Jonsson | Powercell Sweden | 63 | |
| Robert Langer | Moderna | 73 | |
| Jie Wang | BYD Company Limited | 59 | |
| Lavina CFA | Moderna | N/A | |
| Paul Sagan | Moderna | 59 | |
| Kjell Bjornsen | Nel ASA | N/A | |
| Patrik Brouzell | Powercell Sweden | 45 | |
| Hakon Volldal | Nel ASA | 47 | |
| Stein Erdal | Nel ASA | N/A | |
| Ray Jordan | Moderna | N/A | |
| Hasse Johansson | Powercell Sweden | 70 | |
| Hans Hide | Nel ASA | N/A | |
| Tracey Franklin | Moderna | 39 | |
| JingSheng Wu | BYD Company Limited | 60 | |
| Esa Laukkanen | Nel ASA | N/A | |
| Ulrike MD | CureVac NV | 51 | |
| Yubo Lian | BYD Company Limited | 59 | |
| James Mock | Moderna | 46 | |
| Stephen Hoge | Moderna | 42 | |
Management Performance
| Return On Equity | 0.76 | |||
| Return On Asset | 0.43 |
BioNTech SE Leadership Team
Elected by the shareholders, the BioNTech's board of directors comprises two types of representatives: BioNTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioNTech. The board's role is to monitor BioNTech's management team and ensure that shareholders' interests are well served. BioNTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioNTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jens Holstein, CFO Board | ||
| Sylke Maas, VP Strategy | ||
| James Ryan, Sr Counsel | ||
| Michael Boehler, MD Communications | ||
| Ryan Richardson, MD Officer | ||
| Sierk Poetting, COO MD | ||
| Pr MD, CoFounder Board | ||
| Ozlem MD, Chief CoFounder | ||
| Sean Marett, Chief Officer |
BioNTech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioNTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.76 | |||
| Return On Asset | 0.43 | |||
| Profit Margin | 0.56 % | |||
| Operating Margin | 0.68 % | |||
| Current Valuation | 29.68 B | |||
| Shares Outstanding | 242.68 M | |||
| Shares Owned By Insiders | 64.00 % | |||
| Shares Owned By Institutions | 18.41 % | |||
| Price To Earning | 45.99 X | |||
| Price To Book | 2.31 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in BioNTech Stock
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.